RU-58841
RU58841
RU-58841 blocks androgen activity. Experiments investigate prostate PC3 cells and anti-alopecia activity on macaque scalps, without establishing an effective human hair-loss regimen.
Not medical advice. Educational reference only.
- Route
- Topical
What is RU-58841?
RU-58841 is an experimental topical antiandrogen investigated for hair loss. It is a non-peptide compound, and it has no FDA approval. Laboratory work includes prostate PC3 cells, while animal research examines scalp hair loss in macaques and sebaceous glands in rats.
Mechanism of action
RU-58841 blocks androgen activity. Experiments investigate prostate PC3 cells and anti-alopecia activity on macaque scalps, without establishing an effective human hair-loss regimen.
Research indications
Skin Repair
EffectiveProposed skin applications concern collagen production and maintenance of barrier function, without established RU-58841 efficacy.
Anti-Aging
EffectiveExploratory skin applications concern finer skin texture and reduced fine lines, without established RU-58841 efficacy.
Wound Healing
ModeratePotential acceleration of skin-wound repair remains an unestablished application for RU-58841.
Antiandrogen activity in prostate PC3 cells
Cell experiments evaluate the antiandrogen activity of RU-58841 in the PC3 prostate cell line.
In vitro1 reference
Interactions
Medications
CautionConsult your prescriber before combining this compound with any medication.
BPC-157
CompatibleNAD+
CompatibleVitamin D
Compatible
How to reconstitute and inject
- Wash your hands and clean the preparation area before handling the topical product.
- Follow the instructions for the specific formulation. Do not assume that preparation instructions for a pre-formulated GHK-Cu product apply to RU-58841.
- Spread a thin coating over the intended area after cleaning and drying the skin.
- Follow the package storage requirements; where instructed, keep the product at room temperature and shield it from direct sunlight.
- Avoid damaged or irritated skin unless a clinician has specifically instructed otherwise.
What to expect
- Week 1–2
- An early adjustment period may accompany initial effects. Watch for adverse reactions while assessing tolerance.
- Week 2–4
- The main effects may begin to emerge. Change the dose only in accordance with your clinician’s recommendations.
- Week 4–8
- The intended effects may become established during this interval. Review your progress together with your clinician.
- Week 8+
- Reassess the outcome and discuss whether to continue, introduce a cycle break or change the dose. These research expectations do not establish individual treatment outcomes.
Side effects and safety
- Injection-associated redness, bruising or mild pain are general administration risks; they do not establish a topical RU-58841 adverse-effect profile
- Possible allergic reactions, including rash or hives; stop use if these develop
- Responses vary by person; use only the lowest clinician-directed amount, monitor carefully and report unusual symptoms
RU-58841: not approved in the US.
Regulatory status
US
Not approvedFDA — No US approval. Research use does not constitute approval for treatment in humans.
- Rx required
- No
- Telehealth
- N/A
Frequently asked questions
Which dosing approaches are discussed?
The starting approach uses a low dose, followed by titration for the standard approach. Numeric amounts are unspecified, and frequency and route vary by protocol. These qualitative descriptions do not establish a human regimen; consult a qualified clinician.
References
RU 58841, a new specific topical antiandrogen: a candidate for the treatment of androgenetic alopecia (1997)
Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. (1998)
Effects of topical antiandrogen and 5-alpha-reductase inhibitors on sebaceous glands in male fuzzy rats. (1997)